Floyd DN, Langham S, Severac HC et al. The economic and quality-of-life burden of Crohn's disease in europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci 2015;60:299–312.
Bernklev T, Jahnsen J, Schulz T et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005;17:1037–1045.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–523 quiz 524.
Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465–483 quiz 464, 484.
Clark M, Colombel JF, Feagan BC et al. American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease. June 21-23, 2006. Gastroenterology 2007;133:312–339.
D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725–732.
Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537–545.
Dulai PS, Sandborn WJ. Next-generation therapeutics for inflammatory bowel disease. Curr Gastroenterol Rep 2016;18:51.
Dassopoulos T, Cohen RD, Scherl EJ et al. Ulcerative colitis care pathway. Gastroenterology 2015;149:238–245.
Sandborn WJ. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology 2014;147:702–705.
Mocko P, Kawalec P, Pilc A. Safety profile of biologic drugs in the therapy of Crohn disease: a systematic review and network meta-analysis. Pharmacol Rep 2016;68:1237–1243.
Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013;368:6–8.
Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2012;61:459–465.
Billioud V, Laharie D, Filippi J et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011;17:152–159.
Carter CT, Leher H, Smith P et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011;17:385–392.
Kane S, Huo D, Aikens J et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39–43.
Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009;26:936–946.
Bridges JF, Hauber AB, Marshall D et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403–413.
Kievit W, van Huist L, van Riel P et al. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res 2010;62:842–847.
Bederman S, Mahomen N, Kreder H et al. In the eye of the beholder: preferences of patients, family physicians, and surgeons for lumbar spinal surgery. Spine 2010;35:108–115.
Porzsolt F, Clouth J, Deutschmann M et al. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes 2010;8:125.
Whitman CB, Shreay S, Gitlin M et al. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol 2013;8:1942–1951.
Johnson FR, Ozdemir S, Mansfield C et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007;133:769–779.
Lichtenstein GR, Waters HC, Kelly J et al. Assessing drug treatment preferences of patients with Crohn’s disease. Patient 2010;3:113–123.
Hodgkins P, Swinburn P, Solomon D et al. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient 2012;5:33–44.
Johnson FR, Hauber B, Ozdemir S et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm 2010;16:616–628.
Johnson FR, Ozdemir S, Mansfield C et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal 2009;29:121–136.
Bewtra M, Fairchild AO, Gilroy E et al. Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol 2015;110:1675–1681.
Cunningham CE, Deal K, Chen Y. Adaptive choice-based conjoint analysis: a new patient-centered approach to the assessment of health service preferences. Patient 2010;3:257–273.
Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168–2172.
Siegel CA, Levy LC, MacKenzie TA et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1–6.
Martinez B, Dailey F, Almario C et al. Patient understanding of the risks and benefits of biologic therapies in inflammatory bowel disease: insights from a large-scale analysis of social media platforms. Inflamm Bowel Dis 2017;23:1057–1064.
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571–1578.
Almario CV, Chey WD, Spiegel BMR. Prevalence and predictors of irritable bowel syndrome in the United States. Digestive Disease Week: San Diego, CA. 2016.
Almario CV, Chey WD, Spiegel BMR. Burden of gastrointestinal symptoms in the United States: results from a survey of over 71,000 Americans. Digestive Disease Week: San Diego, CA. 2016.
Almario CV, Almario AA, Cunningham ME et al. Old farts–fact or fiction?: results from a population-based survey of 16,000 Americans examining the association between age and flatus. Clin Gastroenterol Hepatol 2017;15:1308–1310.
Spiegel BM, Hays RD, Bolus R et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014;109:1804–1814.
Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. Research Publishers: Madison, WI. 2010.
Baars JE, Markus T, Kuipers EJ et al. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010;81:113–119.
Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 2011;33:23–32.
Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf 2011;10:863–870.
Selinger CP, Eaden J, Jones DB et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2199–2206.
Colliver JA, Swartz MH. Assessing clinical performance with standardized patients. JAMA 1997;278:790–791.
Luck J, Peabody JW, Dresselhaus TR et al. How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med 2000;108:642–649.
Peabody JW, Luck J, Glassman P et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 2004;141:771–780.
Sawtooth Software The Adaptive Choice-Based Conjoint (ACBC) Technical Paper. 2009 [cited 20 2017 October]; Available from https://www.sawtoothsoftware.com/download/techpap/acbctech.pdf.
Randell RL, Long MD, Cook SF et al. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis 2014;20:541–544.